BACKGROUND AND OBJECTIVES: Tuberculosis (TB) is a leading cause of death in HIV-infected patients worldwide. We aimed to study clinical characteristics and outcome of 1075 consecutive patients diagnosed with HIV/TB from 2004 to 2006 in Europe and Argentina. METHODS: One-year mortality was assessed in patients stratified according to region of residence, and factors associated with death were evaluated in multivariable Cox models. RESULTS: At TB diagnosis, patients in Eastern Europe had less advanced immunodeficiency, whereas a greater proportion had a history of intravenous drug use, coinfection with hepatitis C, disseminated TB, and infection with drug-resistant TB (P < 0.0001). In Eastern Europe, fewer patients initiated TB treatment containing at least rifamycin, isoniazid, and pyrazinamide or combination antiretroviral therapy (P < 0.0001). Mortality at 1 year was 27% in Eastern Europe, compared with 7, 9 and 11% in Central/Northern Europe, Southern Europe, and Argentina, respectively (P < 0.0001). In a multivariable model, the adjusted relative hazard of death was significantly lower in each of the other regions compared with Eastern Europe: 0.34 (95% confidence interval 0.17-0.65), 0.28 (0.14-0.57), 0.34 (0.15-0.77) in Argentina, Southern Europe and Central/Northern Europe, respectively. Factors significantly associated with increased mortality were CD4 cell count less than 200 cells/microl [2.31 (1.56-3.45)], prior AIDS [1.74 (1.22-2.47)], disseminated TB [2.00 (1.38-2.85)], initiation of TB treatment not including rifamycin, isoniazid and pyrazinamide [1.68 (1.20-2.36)], and rifamycin resistance [2.10 (1.29-3.41)]. Adjusting for these known confounders did not explain the increased mortality seen in Eastern Europe. CONCLUSION: The poor outcome of patients with HIV/TB in Eastern Europe deserves further study and urgent public health attention.
BACKGROUND AND OBJECTIVES:Tuberculosis (TB) is a leading cause of death in HIV-infectedpatients worldwide. We aimed to study clinical characteristics and outcome of 1075 consecutive patients diagnosed with HIV/TB from 2004 to 2006 in Europe and Argentina. METHODS: One-year mortality was assessed in patients stratified according to region of residence, and factors associated with death were evaluated in multivariable Cox models. RESULTS: At TB diagnosis, patients in Eastern Europe had less advanced immunodeficiency, whereas a greater proportion had a history of intravenous drug use, coinfection with hepatitis C, disseminated TB, and infection with drug-resistant TB (P < 0.0001). In Eastern Europe, fewer patients initiated TB treatment containing at least rifamycin, isoniazid, and pyrazinamide or combination antiretroviral therapy (P < 0.0001). Mortality at 1 year was 27% in Eastern Europe, compared with 7, 9 and 11% in Central/Northern Europe, Southern Europe, and Argentina, respectively (P < 0.0001). In a multivariable model, the adjusted relative hazard of death was significantly lower in each of the other regions compared with Eastern Europe: 0.34 (95% confidence interval 0.17-0.65), 0.28 (0.14-0.57), 0.34 (0.15-0.77) in Argentina, Southern Europe and Central/Northern Europe, respectively. Factors significantly associated with increased mortality were CD4 cell count less than 200 cells/microl [2.31 (1.56-3.45)], prior AIDS [1.74 (1.22-2.47)], disseminated TB [2.00 (1.38-2.85)], initiation of TB treatment not including rifamycin, isoniazid and pyrazinamide [1.68 (1.20-2.36)], and rifamycin resistance [2.10 (1.29-3.41)]. Adjusting for these known confounders did not explain the increased mortality seen in Eastern Europe. CONCLUSION: The poor outcome of patients with HIV/TB in Eastern Europe deserves further study and urgent public health attention.
Authors: Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland Journal: Lancet Date: 2010-07-31 Impact factor: 79.321
Authors: Josiah D Rich; David A Wohl; Curt G Beckwith; Anne C Spaulding; Nathaniel E Lepp; Jacques Baillargeon; Adrian Gardner; Ann Avery; Frederick L Altice; Sandra Springer Journal: Curr HIV/AIDS Rep Date: 2011-12 Impact factor: 5.071
Authors: Yuri A Amirkhanian; Jeffrey A Kelly; Anna V Kuznetsova; Wayne J DiFranceisco; Vladimir B Musatov; Dmitry G Pirogov Journal: AIDS Behav Date: 2011-05
Authors: M Mansfeld; A Skrahina; L Shepherd; A Schultze; A M Panteleev; R F Miller; J M Miro; I Zeltina; S Tetradov; H Furrer; O Kirk; A Grzeszczuk; N Bolokadze; A Matteelli; F A Post; J D Lundgren; A Mocroft; Amw Efsen; D N Podlekareva Journal: HIV Med Date: 2015-05-11 Impact factor: 3.180
Authors: Nikoloz Chkhartishvili; Lali Sharvadze; Otar Chokoshvili; Natalia Bolokadze; Nino Rukhadze; Russell R Kempker; Amiran Gamkrelidze; Jack A DeHovitz; Carlos Del Rio; Tengiz Tsertsvadze Journal: AIDS Res Hum Retroviruses Date: 2014-02-24 Impact factor: 2.205
Authors: Jose M Miro; Christian Manzardo; Cristina Mussini; Margaret Johnson; Antonella d'Arminio Monforte; Andrea Antinori; M John Gill; Laura Sighinolfi; Caterina Uberti-Foppa; Vanni Borghi; Caroline Sabin Journal: PLoS One Date: 2011-10-17 Impact factor: 3.240
Authors: Anne Marie W Efsen; Anna Schultze; Frank A Post; Alexander Panteleev; Hansjakob Furrer; Robert F Miller; Marcelo H Losso; Javier Toibaro; Aliaksandr Skrahin; Jose M Miro; Joan A Caylà; Enrico Girardi; Mathias Bruyand; Niels Obel; Daria N Podlekareva; Jens D Lundgren; Amanda Mocroft; Ole Kirk Journal: PLoS One Date: 2015-12-30 Impact factor: 3.240